logo-loader
Instem PLC

Instem plc - Director/PDMR Shareholding

RNS Number : 1972A
Instem plc
24 May 2019
 

Instem plc
("Instem" or the "Company")

Director/PDMR Shareholding

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, was notified on 22 May 2019, that Mike McGoun, a Non-Executive Director of the Company, sold 30,000 ordinary shares of 10p each in the Company ("Ordinary Shares") on 21 May 2019 at a price of 347.55 pence per Ordinary Share.

Following the transaction, Mike now has a total interest in 6,786 Ordinary Shares, representing approximately 0.04% of the Company's issued share capital

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

 

Mike McGoun

 

2

Reason for the notification

a)

 

Position/status

Non Executive Director

b)

 

Initial notification /Amendment

Initial

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

 

Instem plc

b)

 

LEI

 

 

213800PILYUFNNROQX68

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 10p each



Identification code

GB00B3TQCK30



b)

 

Nature of the transaction

Sale of ordinary shares

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




347.55p

30,000







d)

 

Aggregated information




- Aggregated volume

30,000



- Price

£104,265.00



e)

 

Date of the transaction

21 May 2019

f)

Place of the transaction

London Stock Exchange (XLON)

 

For further information, please contact:

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO


Nigel Goldsmith, CFO




 

N+1 Singer (Nominated Adviser & Broker)

 

+44 (0) 20 7496 3000

Richard Lindley

Rachel Hayes




 

Walbrook Financial PR

 

+44 (0) 20 7933 8780

Paul Cornelius

instem@walbrookpr.com

Nick Rome

Sam Allen

 




About Instem 

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

Instem solutions are in use by customers worldwide and enable our clients to bring life enhancing products to market faster.

 Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.

To learn more about Instem solutions and its mission, please visit instem.com.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBLGDUBGDBGCS
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

Instem proves in step with groundbreaking market needs as it posts strong...

Phil Reason, CEO of Instem PLC (AIM:INS), joined Proactive with details of the company's 2022 financial performance. The company grew revenues by 28% and underlying earnings were up 32%. It also said it expected to benefit in 2023 from ‘industry consolidation’. Recent success include...

on 15/5/23

3 min read